Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in alzheimer brains

NeuroReport

Volumn 6, Issue 17, 1995, Pages 2419-2423

  Warpman, Ulrika ^a,b,c   Nordberg, Agneta ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

ABT 418; Alzheimer s disease; Epibatidine; Human brain; Nicotinic receptor subtypes; Temporal cortex; 3H cytisine; 3H nicotine

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; EPIBATIDINE; NICOTINIC RECEPTOR; RECEPTOR SUBUNIT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RECEPTOR BINDING; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALKALOIDS; ALZHEIMER DISEASE; ANIMALS; ANTI-ANXIETY AGENTS; AZOCINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CELLS, CULTURED; HUMANS; ISOXAZOLES; KINETICS; MICE; NICOTINE; NICOTINIC AGONISTS; PYRIDINES; PYRROLIDINES; QUINOLIZINES; RECEPTORS, NICOTINIC; TEMPORAL LOBE; TRANSFECTION;

EID: 0029586823     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/00001756-199511270-00033     Document Type: Article

References (24)

1. Nordberg A, Alafuzoff I and Winblad B. J Neurosci Res 31, 103-111 (1992).
2. Nordberg A, Adem A, Hardy J. Neurosci Lett 86, 317-321 (1988).
3. Sargent PB. Annu Rev Neurosci 16, 403-443 (1993).
4. Wevers A, Jeske A, Lobron C. Mol Brain Res 25, 122-128 (1994).
5. Rubboli F, Court JA, Morris C. Neurochem Int 25, 69-71 (1994).
6. Wartburton DM, Rusted JM and Fowler J. Psychopharmacology 108, 443-447 (1992).
7. Sahakian B, Jones G, Levy R. Br J Psychiatry 154, 797-800 (1989).
8. Newhouse PA, Sunderland T, Tariot PN. Psychopharmacology 95, 171-175 (1988).
9. Jones GMM, Sahakian BJ, Levy R. Psychopharmacology 108, 485-494 (1992).
10. Nordberg A, Winblad B. Neurosci Lett 72, 115-119 (1986).
11. Whitehouse PJ, Martino AM, Antuono PG. Brain Res 371,146-151 (1986).
12. Nordberg A, Hartvig P, Lilja A. J Neural Transm (P-D section) 2, 215-224 (1990).
13. Nordberg A, Lundqvist H, Hartvig P. Alzheimer’s Dis Assoc Disord 9, 21-27 (1985).
14. Spande TF, Garraffo HM, Edwards HJ. J Am Chem Soc 114, 3475-3478 (1992).
15. Arneric S, Sullivan P, Briggs C. J Pharmacol Exp Ther 270. 310-318 (1994).
16. Gray EG and Whittaker VP. J Anat 96, 79-88 (1962).
17. Lowry OH, Rosenbrough NJ, Farr AL. J Biol Chem 193, 265-275 (1951).
18. Whiting PJ, Esch F, Shimasaki S. FEBS Lett 219, 459-463 (1987).
19. Zhang X, Ze-Hui G, Hellstrom-Lindahl E. NeuroReport 6, 313-317 (1994).
20. McPherson GA. J Pharmacol Methods 14, 213-228 (1985).
21. Flores CM, Rogers SW, Pabreza LA. Mol Pharmacol 41, 31-37 (1992).
22. Badio B and Daly JW. Mol Pharmacol 45, 563-569 (1994).
23. Sullivan JP, Decker MW, Brioni JD. J Pharmacol Exp Ther 271, 624-631 (1994).
24. Houghtling RA, Davila-Garcia ML, Hurt S. Med Chem Res 4, 538-546 (1994).